The NAA25 antibody is a research tool designed to detect the NAA25 protein, a critical subunit of the NatB complex involved in N-terminal acetylation—a widespread co-translational protein modification. NAA25. also known as NAT5 or hNaa25p, partners with NAA20 to form the NatB complex, which specifically acetylates methionine residues followed by acidic amino acids in nascent polypeptides. This modification influences protein stability, localization, and interactions, impacting cellular processes like cell cycle progression, apoptosis, and stress responses.
Studies link NAA25 dysregulation to diseases, including cancers. For instance, reduced NAA25 expression correlates with poor prognosis in hepatocellular carcinoma and breast cancer, suggesting its role as a potential tumor suppressor. Conversely, elevated levels in some malignancies hint at context-dependent functions.
NAA25 antibodies, typically raised in rabbits or mice as monoclonal or polyclonal versions, are essential for investigating NatB-mediated acetylation mechanisms. They enable techniques like Western blotting, immunofluorescence, and immunohistochemistry to assess protein expression patterns in tissues or cultured cells. Researchers also use these antibodies to validate NAA25 knockout models or study post-translational modifications. Recent efforts focus on optimizing antibody specificity and sensitivity to address cross-reactivity challenges, enhancing their utility in both basic research and clinical biomarker discovery. Understanding NAA25's role through such antibodies may unveil therapeutic targets for diseases linked to acetylation defects.